dc.contributor.author | Peters, S | |
dc.contributor.author | Scherpereel, A | |
dc.contributor.author | Cornelissen, R | |
dc.contributor.author | Oulkhouir, Y | |
dc.contributor.author | Greillier, L | |
dc.contributor.author | Kaplan, MA | |
dc.contributor.author | Talbot, T | |
dc.contributor.author | Monnet, I | |
dc.contributor.author | Hiret, S | |
dc.contributor.author | Baas, P | |
dc.contributor.author | Nowak, AK | |
dc.contributor.author | Fujimoto, N | |
dc.contributor.author | Tsao, AS | |
dc.contributor.author | Mansfield, AS | |
dc.contributor.author | Popat, S | |
dc.contributor.author | Zhang, X | |
dc.contributor.author | Hu, N | |
dc.contributor.author | Balli, D | |
dc.contributor.author | Spires, T | |
dc.contributor.author | Zalcman, G | |
dc.date.accessioned | 2022-04-27T12:14:05Z | |
dc.date.available | 2022-04-27T12:14:05Z | |
dc.date.issued | 2022-02-03 | |
dc.identifier.citation | Annals of oncology : official journal of the European Society for Medical Oncology, 2022 | en |
dc.identifier.issn | 0923-7534 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5100 | |
dc.identifier.eissn | 1569-8041 | en_US |
dc.identifier.eissn | 1569-8041 | |
dc.identifier.doi | 10.1016/j.annonc.2022.01.074 | en_US |
dc.identifier.doi | 10.1016/j.annonc.2022.01.074 | |
dc.description.abstract | <h4>Background</h4>In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data with 3-year minimum follow-up.<h4>Patients and methods</h4>Adults with previously untreated, histologically confirmed, unresectable MPM and Eastern Cooperative Oncology Group performance status of ≤1 were randomized 1 : 1 to nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) for up to 2 years, or six cycles of platinum plus pemetrexed chemotherapy. This report includes updated efficacy and safety outcomes, exploratory biomarker analyses including four-gene inflammatory expression signature score, and a post hoc efficacy analysis in patients who discontinued treatment due to treatment-related adverse events (TRAEs).<h4>Results</h4>With a median follow-up of 43.1 months, nivolumab plus ipilimumab continued to prolong OS versus chemotherapy. Median OS was 18.1 versus 14.1 months [hazard ratio (95% confidence interval), 0.73 (0.61-0.87)], and 3-year OS rates were 23% versus 15%, respectively. Three-year progression-free survival rates were 14% versus 1%, and objective response rates were 40% versus 44%. At 3 years, 28% versus 0% of responders had an ongoing response. Improved survival benefit with nivolumab plus ipilimumab versus chemotherapy was observed across subgroups, including histology. A high score of the four-gene inflammatory signature appeared to correlate with improved survival benefit with nivolumab plus ipilimumab. No new safety signals were observed with nivolumab plus ipilimumab, despite patients being off therapy for 1 year. In patients who discontinued nivolumab plus ipilimumab due to TRAEs, median OS was 25.4 months, and 34% of responders maintained their responses for ≥3 years after discontinuation.<h4>Conclusions</h4>With 3 years' minimum follow-up, nivolumab plus ipilimumab continued to provide long-term survival benefit over chemotherapy and a manageable safety profile, supporting the regimen as standard-of-care treatment for unresectable MPM, regardless of histology. | en_US |
dc.format | Print-Electronic | en_US |
dc.language | eng | en_US |
dc.language.iso | eng | en |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en |
dc.title | First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. | en |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-01-24 | |
rioxxterms.version | VoR | en |
rioxxterms.versionofrecord | 10.1016/j.annonc.2022.01.074 | en |
rioxxterms.licenseref.startdate | 2022-02-03 | |
dc.relation.isPartOf | Annals of oncology : official journal of the European Society for Medical Oncology | en_US |
pubs.notes | Not known | en_US |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published | en_US |
pubs.embargo.terms | Not known | en_US |
icr.researchteam | Thoracic Oncology | |
dc.contributor.icrauthor | Popat, Sanjay | |